The recent approval of Aucatzyl by the FDA marks a significant advancement in the treatment landscape for patients with B-cell precursor acute lymphoblastic leukemia, especially those whose disease has progressed following initial chemotherapy treatments. Developed by U.K.-based Autolus
The victory of Donald Trump in the U.S. presidential election has sparked widespread speculation about the potential changes within federal health agencies, particularly the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC). Trump's past and potential future choices for
The biopharma industry in the United States continues to thrive, driven by innovation, substantial funding, and strategic collaborations. As we look ahead to 2024, certain regions stand out as leading hubs for biopharma activity. The evolution of these hubs is fueled by various factors, including
In a significant move just three years post its highly successful IPO, Sana Biotechnology has announced a strategic restructuring that will likely reshape the company's future and impact. This overhaul will include layoffs and a refocused research directive, marking a notable shift in
In today's rapidly evolving field of biomanufacturing, traditional methods often fall short of the rigorous demands for real-time data and consistent product quality. Laser Force Cytology (LFC) has emerged as an innovative, label-free technology that offers a transformative approach to
The ongoing search for better and safer treatments for multiple myeloma, a type of blood cancer, has taken a significant step forward with the development of a new cell therapy by Arcellx and Gilead Sciences. The pioneering approach demonstrated a substantial reduction or total eradication of
